oncology target
- Business Wire
RubrYc Therapeutics Announces a Research Collaboration and License Option Agreement With Zai Labs
SAN CARLOS, Calif.–(BUSINESS WIRE)–RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies, today announced that it has entered…
Read More »